Work

Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125]

Year: 2018

Type: erratum

Abstract: The authors regret there was an error on page 120. The paragraph should read as follows (the correction has been underlined):As of the July 01, 2017, data cutoff date for OS with a median follow-up of 34.5 months (IQR 31.4–40.4), 90 deaths had occurred (43 of 79 patients in the cabozantinib group and 47 of 78 patients in the sunitinib group). The authors would like to apologise for any inconvenience caused. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival updateEuropean Journal of CancerVol. 94PreviewThe randomised phase 2 CABOSUN trial comparing cabozantinib with sunitinib as initial therapy for advanced renal cell carcinoma (RCC) of intermediate or poor risk met the primary end-point of improving progression-free survival (PFS) as assessed by investigator. We report PFS by independent radiology review committee (IRC) assessment, ORR per IRC and updated overall survival (OS). Full-Text PDF Open Access

Source: European Journal of Cancer

DOI: 10.1016/j.ejca.2018.09.022